For that to occur the Data would have to diametrically oppose...

For that to occur the Data would have to diametrically oppose the previous 2 x positive Interim Phase II announcements.

Plus from looking at the previous Data , there was a direct correlation that benefit was increasing with longer duration exposure to SNT 5505.

On top of that Gary has made a statement that the last two data sets has "De-risked the Treatment"

If it were me at SNT i would be utilising this long awaited new Phase II data to Rerate / Revalue the Company and be promoting the arse out of the full suite of Company Offerings...

First we need to climb over 7c ,,,, sometimes when you see these Companies do FA promotion you wonder if its to keep it suppressed for a pre ordained deal ?? because SNT falls into the deal zone once this data drops.... any fence sitter or even those that have made themselves known may utilise the Positive Phase II Data as a Milestone for Entry $$$$....

I'm in the camp of ,,Data will be Positive ,, we have a resident Science Professional who digs even deeper than I do ,, and he and his advisor only see a continuation of Positive data,, remember the 2nd Interim Data Analysis only had a few Patients that were still in Trial mode , the majority of trialing over the past 16 months was completed prior to the April 29th Positive Announcement.

Syntara’s abstract, titled ‘A PHASE 1/2A TRIAL OF PXS-5505, A NOVEL PAN-LYSYL OXIDASE
INHIBITOR, IN PATIENTS WITH ADVANCED MYELOFIBROSIS’, will be presented in Poster
Session 2 at 18:30 – 19:30 CEST, Saturday 14 June (02:30 – 03:30 AEST, Sunday 15 June).
The 30th EHA Congress is being held in Milan, Italy from 12-15 June 2025, and is a highly
regarded forum for original data, haematological innovation and evidence-based
knowledge of primary clinical relevance.

Syntara CEO Gary Phillips said: "We’re proud to see SNT-5505 selected for a poster
presentation at one of the premier haematology events worldwide in the EHA2025
Congress. This highlights the growing recognition of the potential impact of this program,
following strong early data presented at ASH2024. The timing of the conference aligns
well with the company receiving a substantial amount of additional data from the
ongoing myelofibrosis trial and facilitates peer review by the world’s leading
haematologists. We look forward to bringing the update to shareholders at the same
time.”
It should be noted that while abstracts for the EHA2025 Congress will be published on 14
May 2025, the abstract relevant to Syntara’s SNT-5505 will only describe the study and will
not contain the new data. The new data will only be presented at the time of the event,
while being announced to the ASX within its continuous disclosure obligations.

You don't fly to Milan to deliver poor data...NZT